Susceptibility to and stratification for monoaminergic antidepressants

US10059996B2 · kind B2 · utility

Assignees

• MEDIZINISCHE HOCHSCHULE HANNOVER · DE
• Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Helge Frieling · Hannover, DE
• André Tadic · Bad Berneck im Fichtelgebirge, DE
• Stefan Bleich · Burgdorf, DE
• Klaus J. Lieb · Mainz, DE

Key dates

• Filing date: May 8, 2013
• Grant date: Aug 28, 2018
• Expiry date: Jun 19, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed.